Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Moleculin's Annamycin Shows 40% CRc in Pivotal AML Trial

Moleculin Biotech, Inc. reported its first quarter 2026 financial results and provided a significant clinical update on its pivotal MIRACLE Phase 2B/3 trial. The trial, evaluating Annamycin in combination with cytarabine (AnnAraC) for relapsed/refractory acute myeloid leukemia (AML), achieved enrollment of 45 subjects. Preliminary blinded results continue to show an encouraging 40% composite complete remission (CRc) rate at both the 30-subject and 45-subject marks. The first interim unblinding of data for these 45 subjects is anticipated in June 2026. The company emphasized Annamycin's potential to address cardiotoxicity, a key limitation of standard anthracyclines. Financially, Moleculin secured approximately $8.3 million in gross proceeds from financing transactions during Q1 2026, extending its operating runway into the third quarter of 2026.

• The pivotal MIRACLE Phase 2B/3 trial for Annamycin (AnnAraC) in relapsed/refractory AML continues to demonstrate promising preliminary blinded efficacy. The trial has observed a consistent 40% composite complete remission (CRc) rate among the first 30 and 45 subjects treated, reinforcing the drug's potential to significantly improve outcomes for patients facing this challenging blood cancer.
• Moleculin is rapidly approaching key clinical milestones for the MIRACLE trial, with the first interim unblinding of data for 45 subjects expected in June 2026. Enrollment for Part A is on track to reach 90 subjects by Q3 2026, followed by its unblinding. The company plans to initiate Part B in the second half of 2026 and anticipates beginning a Rolling New Drug Application (NDA) submission for accelerated approval in 2028 based on the primary endpoint of complete remission.
• Annamycin is highlighted for its potential to redefine the anthracycline class by avoiding the cardiotoxicity commonly associated with existing therapies, thereby expanding treatment options for patients who might otherwise be ineligible due to lifetime dose limits. Furthermore, Moleculin strengthened its financial position in Q1 2026, securing approximately $8.3 million in gross proceeds from financing, which is expected to support planned operations into the third quarter of 2026.

Unpacking the Pivotal MIRACLE Trial Design and Milestones

The literature reveals several important clinical trials investigating relapsed or refractory acute myeloid leukemia (R/R AML), spanning from early-phase dose-finding studies to real-world effectiveness analyses. These trials demonstrate diverse therapeutic approaches including novel targeted agents, combination chemotherapy regimens, and epigenetic modulators.

Addressing Key Limitations in Relapsed/Refractory AML Treatment

Relapsed/refractory AML remains one of the most challenging hematologic malignancies, with more than 50% of patients dying from relapsed disease despite significant advances in understanding molecular pathogenesis. Current treatment approaches face multiple limitations spanning therapeutic options, resistance mechanisms, and patient eligibility criteria. These challenges are compounded by substantial economic burden and the urgent need for more effective, tolerable therapies.

• Limited curative options and poor prognosis — Allogeneic bone marrow transplantation in second complete remission remains the only potential curative option for R/R AML patients, which is particularly difficult to achieve in patients with primary induction failure or those older than 65 years, while patients ineligible for aggressive chemotherapy and transplantation face extremely poor outcomes

• Therapy resistance and relapse mechanisms — Achieving durable responses represents a major challenge due to intrinsic and acquired resistance mechanisms, including acquired mutations altering drug targets, co-occurring genetic and epigenetic alterations, activation of bypass signaling pathways, metabolic reprogramming, and the increasingly recognized roles of clonal heterogeneity and bone marrow microenvironment

• Lack of established standard of care — Primary refractory disease and relapse remain frequent with no clearly established standard of care in the R/R setting, and despite approval of 8 new drugs since 2017, significant questions remain about optimal treatment selection and sequencing

• Uncertainty regarding venetoclax-based combinations — While HMA/venetoclax is standard front-line therapy for patients ineligible for intensive chemotherapy, its efficacy in R/R setting remains poorly defined, with meta-analysis showing modest response rates (CR 26%, composite CR 43%) and median overall survival of only 8 months, accompanied by significant grade ≥3 toxicities

• CAR-T cell therapy limitations — Application of CAR-T therapy in AML faces significant barriers including scarcity of suitable tumor-target antigens, most AML-associated surface antigens being expressed on healthy hematopoietic cells creating on-target/off-tumor toxicity risks, early relapses, and severe toxicities limiting clinical utility

• Diagnostic and resistance prediction challenges — Current resistance prediction methods are often slow and inaccessible in clinical settings, delaying crucial treatment adjustments, with urgent need for rapid, reliable diagnostic tools to identify chemoresistance early and enable personalized therapeutic strategies

• Substantial economic and healthcare resource burden — R/R AML patients face mean total episode costs of $439,104, with inpatient visits accounting for the greatest component ($308,978), while patients undergoing HSCT experience longer episodes of care, higher costs, and more symptoms and toxicities compared to those without transplant

Annamycin's Dual Promise in Relapsed/Refractory AML

The recent update on Annamycin's pivotal MIRACLE trial in relapsed/refractory acute myeloid leukemia (AML) signals a potentially transformative moment for patients facing this aggressive and often treatment-resistant cancer. The preliminary blinded 40% composite complete remission rate is particularly noteworthy given the high unmet need in this patient population, where conventional therapies frequently fall short.

Annamycin is not just another anthracycline; research indicates it possesses unique properties that could redefine the utility of this drug class. A key differentiator for Annamycin is its significantly reduced cardiotoxicity compared to traditional anthracyclines like doxorubicin, a critical advantage for AML patients who may have pre-existing cardiac conditions or have received prior cardiotoxic treatments. Furthermore, studies show Annamycin's ability to circumvent common multidrug resistance mechanisms, including those mediated by P-glycoprotein and the multidrug resistance-associated protein (MRP). This dual advantage—reduced cardiac risk and efficacy against resistant cells—positions Annamycin to potentially treat patients who currently have very limited options. The strategic use of a liposomal formulation also appears to enhance its pharmacokinetics and tumor targeting, further improving its therapeutic profile.

However, the path forward is not without its considerations. The 40% CRc rate, while encouraging, is preliminary and blinded, meaning the final unblinded data in June 2026 will be crucial in determining the trial's ultimate success. While cardiotoxicity is mitigated, other adverse events, such as mucositis and gastrointestinal issues observed in prior studies, will need careful management in this vulnerable patient group. From a corporate perspective, the company's financial runway extending only into the third quarter of 2026 highlights the urgency for positive trial outcomes and potential strategic partnerships or further financing to support continued development and commercialization. Should the positive trends hold, Annamycin could emerge as a vital new tool, offering renewed hope for patients with relapsed/refractory AML and validating a novel approach to overcoming long-standing challenges in cancer chemotherapy.